MedTrace Logo

Muscular Synergies and Behavioral Adaptations of Gait in Pain Anticipation (SYAMAPP)

NCT06929559 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2025-09-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether the anticipation of pain influences gait control and psychophysiological responses in healthy individuals. Participants will receive a neutral cream described either as potentially painful (experimental group) or inert (control group), and their behavioral and physiological adaptations will be measured during walking tasks.

Conditions

  • Nocebo Effect
  • Pain Anticipation

Interventions

OTHER

Pain expectation conditioning

Participants receive application of a neutral cream (MEDICAFARM) with verbal and behavioral suggestions that it may cause localized pain. Researchers wear gloves during application and emphasize potential discomfort, stating effects may intensify with movement.

OTHER

Comparator (Control Group)

Participants receive identical application of the neutral cream but are informed it is inert and harmless. Researchers apply the cream without gloves and provide neutral instructions.

OTHER

Intervention: Gait

Participants undergo assessment procedures including: * Pre- and post-application gait analysis (GAITRite mat, Zebris treadmill) * Physiological monitoring (EMG, HRV, EDA) * Identical questionnaires (BPI, TSK, FACS, PCS, VAS)

Sponsors & Collaborators

  • Universite de Picardie Jules Verne

    lead OTHER

Principal Investigators

  • Thierry Lelard, PhD · Lecturer

  • Maryne Cozette, PhD · Lecturer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2025-10-30
Completion
2028-10-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06929559 on ClinicalTrials.gov